96
Participants
Start Date
July 6, 2022
Primary Completion Date
September 20, 2024
Study Completion Date
September 20, 2024
Daratumumab
intravenous or subcutaneous
Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main
iOMEDICO AG
INDUSTRY